BioLife Solutions Inc
BLFS24.900USD
-0.510-2.01%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.19BMarket Cap
LossP/E TTM
More Details of BioLife Solutions Inc Company
BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
BioLife Solutions Inc Info
Ticker SymbolBLFS
Company nameBioLife Solutions Inc
IPO dateNov 22, 1989
CEODe Greef (Roderick)
Number of employees159
Security typeOrdinary Share
Fiscal year-endNov 22
AddressSuite 310
CityBOTHELL
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code98021
Phone14254011400
Websitehttps://www.biolifesolutions.com/
Ticker SymbolBLFS
IPO dateNov 22, 1989
CEODe Greef (Roderick)
Company Executives of BioLife Solutions Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Aby J. Mathew, Ph.D.
Dr. Aby J. Mathew, Ph.D.
Chief Scientific Officer, Executive Vice President
Chief Scientific Officer, Executive Vice President
252.89K
-0.21%
Ms. Karen A. Foster
Ms. Karen A. Foster
Chief Quality and Operations Officer
Chief Quality and Operations Officer
150.11K
-0.28%
Mr. Todd Berard
Mr. Todd Berard
Chief Commercial Officer
Chief Commercial Officer
98.49K
-0.31%
Mr. Roderick De Greef
Mr. Roderick De Greef
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
81.02K
-31.81%
Mr. Troy Wichterman
Mr. Troy Wichterman
Chief Financial Officer
Chief Financial Officer
68.75K
-30.38%
Ms. Sarah Aebersold
Ms. Sarah Aebersold
Chief Human Resources Officer
Chief Human Resources Officer
49.99K
-0.43%
Mr. Joydeep Goswami
Mr. Joydeep Goswami
Independent Director
Independent Director
38.11K
-7.30%
Sean Werner
Sean Werner
Chief Technology Officer
Chief Technology Officer
25.93K
-0.42%
Ms. Amy Duross
Ms. Amy Duross
Lead Independent Director
Lead Independent Director
13.81K
-42.00%
Ms. Catherine (Cathy) Coste, CPA
Ms. Catherine (Cathy) Coste, CPA
Independent Director
Independent Director
5.70K
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Aby J. Mathew, Ph.D.
Dr. Aby J. Mathew, Ph.D.
Chief Scientific Officer, Executive Vice President
Chief Scientific Officer, Executive Vice President
252.89K
-0.21%
Ms. Karen A. Foster
Ms. Karen A. Foster
Chief Quality and Operations Officer
Chief Quality and Operations Officer
150.11K
-0.28%
Mr. Todd Berard
Mr. Todd Berard
Chief Commercial Officer
Chief Commercial Officer
98.49K
-0.31%
Mr. Roderick De Greef
Mr. Roderick De Greef
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
81.02K
-31.81%
Mr. Troy Wichterman
Mr. Troy Wichterman
Chief Financial Officer
Chief Financial Officer
68.75K
-30.38%
Ms. Sarah Aebersold
Ms. Sarah Aebersold
Chief Human Resources Officer
Chief Human Resources Officer
49.99K
-0.43%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Product Revenue-Cell processing
22.90M
90.08%
Rental Revenue- Evo and thaw
1.68M
6.59%
Product Revenue- Evo and thaw
811.00K
3.19%
Service Revenue-Evo and thaw
36.00K
0.14%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Product Revenue-Cell processing
22.90M
90.08%
Rental Revenue- Evo and thaw
1.68M
6.59%
Product Revenue- Evo and thaw
811.00K
3.19%
Service Revenue-Evo and thaw
36.00K
0.14%
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Casdin Capital, LLC
12.37%
BlackRock Institutional Trust Company, N.A.
10.60%
T. Rowe Price Investment Management, Inc.
8.45%
Invesco Advisers, Inc.
7.22%
The Vanguard Group, Inc.
6.15%
Other
55.21%
Shareholders
Shareholders
Proportion
Casdin Capital, LLC
12.37%
BlackRock Institutional Trust Company, N.A.
10.60%
T. Rowe Price Investment Management, Inc.
8.45%
Invesco Advisers, Inc.
7.22%
The Vanguard Group, Inc.
6.15%
Other
55.21%
Shareholder Types
Shareholders
Proportion
Investment Advisor
49.20%
Investment Advisor/Hedge Fund
34.12%
Hedge Fund
15.54%
Research Firm
2.32%
Individual Investor
2.00%
Pension Fund
1.60%
Bank and Trust
0.65%
Sovereign Wealth Fund
0.08%
Insurance Company
0.03%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
402
49.86M
109.33%
-743.44K
2025Q3
418
50.60M
112.73%
+431.43K
2025Q2
417
51.14M
109.98%
+2.32M
2025Q1
412
48.78M
108.79%
-2.89M
2024Q4
397
47.68M
109.40%
+879.99K
2024Q3
391
46.15M
113.67%
-1.38M
2024Q2
371
47.55M
108.21%
+1.88M
2024Q1
363
45.48M
113.98%
-6.15M
2023Q4
383
46.46M
115.88%
+36.24K
2023Q3
386
44.68M
106.82%
+2.82M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Casdin Capital, LLC
6.71M
14%
-1.00M
-12.97%
Aug 15, 2025
BlackRock Institutional Trust Company, N.A.
5.08M
10.61%
+12.43K
+0.25%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
4.25M
8.86%
+2.90M
+215.04%
Jun 30, 2025
Invesco Advisers, Inc.
3.46M
7.22%
+126.62K
+3.80%
Jun 30, 2025
The Vanguard Group, Inc.
2.89M
6.03%
+93.13K
+3.33%
Jun 30, 2025
State Street Investment Management (US)
1.41M
2.94%
-24.84K
-1.73%
Jun 30, 2025
Fred Alger Management, LLC
1.25M
2.61%
-285.09K
-18.60%
Jun 30, 2025
MFS Investment Management
1.10M
2.3%
+337.42K
+44.13%
Jun 30, 2025
Rockefeller Capital Management
1.03M
2.14%
+62.16K
+6.45%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco S&P SmallCap Health Care ETF
0.66%
Invesco S&P SmallCap 600 Pure Growth ETF
0.62%
First Trust Multi-Manager Small Cap Opportunities ETF
0.52%
Zacks Small/Mid Cap ETF
0.41%
iShares Micro-Cap ETF
0.2%
State Street SPDR S&P 600 Small Cap Growth ETF
0.15%
First Trust Small Cap Growth AlphaDEX Fund
0.15%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.14%
iShares S&P Small-Cap 600 Growth ETF
0.14%
iShares ESG Select Screened S&P Small-Cap ETF
0.09%
View more
Invesco S&P SmallCap Health Care ETF
Proportion0.66%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion0.62%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.52%
Zacks Small/Mid Cap ETF
Proportion0.41%
iShares Micro-Cap ETF
Proportion0.2%
State Street SPDR S&P 600 Small Cap Growth ETF
Proportion0.15%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.15%
Vanguard S&P Small-Cap 600 Growth Index Fund
Proportion0.14%
iShares S&P Small-Cap 600 Growth ETF
Proportion0.14%
iShares ESG Select Screened S&P Small-Cap ETF
Proportion0.09%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of BioLife Solutions Inc?
The top five shareholders of BioLife Solutions Inc are:
Casdin Capital, LLC holds 6.71M shares, accounting for 14.00% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.08M shares, accounting for 10.61% of the total shares.
T. Rowe Price Investment Management, Inc. holds 4.25M shares, accounting for 8.86% of the total shares.
Invesco Advisers, Inc. holds 3.46M shares, accounting for 7.22% of the total shares.
The Vanguard Group, Inc. holds 2.89M shares, accounting for 6.03% of the total shares.
Casdin Capital, LLC holds 6.71M shares, accounting for 14.00% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.08M shares, accounting for 10.61% of the total shares.
T. Rowe Price Investment Management, Inc. holds 4.25M shares, accounting for 8.86% of the total shares.
Invesco Advisers, Inc. holds 3.46M shares, accounting for 7.22% of the total shares.
The Vanguard Group, Inc. holds 2.89M shares, accounting for 6.03% of the total shares.
What are the top three shareholder types of BioLife Solutions Inc?
The top three shareholder types of BioLife Solutions Inc are:
Casdin Capital, LLC
BlackRock Institutional Trust Company, N.A.
T. Rowe Price Investment Management, Inc.
Casdin Capital, LLC
BlackRock Institutional Trust Company, N.A.
T. Rowe Price Investment Management, Inc.
How many institutions hold shares of BioLife Solutions Inc (BLFS)?
As of 2025Q4, 402 institutions hold shares of BioLife Solutions Inc, with a combined market value of approximately 49.86M, accounting for 109.33% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -3.40%.
What is the biggest source of revenue for BioLife Solutions Inc?
In FY2025Q2, the Product Revenue-Cell processing business generated the highest revenue for BioLife Solutions Inc, amounting to 22.90M and accounting for 90.08% of total revenue.
